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Neural regulation of the kidney
function in rats with cisplatin induced
renal failure
Niamh E. Goulding and Edward J. Johns*
Renal Research Laboratory, Department of Physiology, University College Cork, Cork, Ireland
Aim: Chronic kidney disease (CKD) is often associated with a disturbed cardiovascular
homeostasis. This investigation explored the role of the renal innervation in mediating
deranged baroreflex control of renal sympathetic nerve activity (RSNA) and renal
excretory function in cisplatin-induced renal failure.
Methods: Rats were either intact or bilaterally renally denervated 4 days prior to receiving
cisplatin (5mg/kg i.p.) and entered a chronic metabolic study for 8 days. At day 8, other
groups of rats were prepared for acute measurement of RSNA or renal function with
either intact or denervated kidneys.
Results: Following the cisplatin challenge, creatinine clearance was 50% lower while
fractional sodium excretion and renal cortical and medullary TGF-β1 concentrations were
3–4 fold higher in both intact and renally denervated rats compared to control rats. In
cisplatin-treated rats, the maximal gain of the high-pressure baroreflex curve was only
20% that of control rats, but following renal denervation not different from that of renally
denervated control rats. Volume expansion reduced RSNA by 50% in control and in
cisplatin-treated rats but only following bilateral renal denervation. The volume expansion
mediated natriuresis/diuresis was absent in the cisplatin-treated rats but was normalized
following renal denervation.
Conclusions: Cisplatin-induced renal injury impaired renal function and caused a
sympatho-excitation with blunting of high and low pressure baroreflex regulation of
RSNA, which was dependent on the renal innervation. It is suggested that in man with
CKD there is a dysregulation of the neural control of the kidney mediated by its sensory
innervation.
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Introduction
Chronic kidney disease (CKD) is often initiated as a consequence of structural deterioration within
the renal vascular and tubular structures and impairs renal function which eventually impinges
on cardiovascular homeostasis (Khawaja and Wilcox, 2011; Sobotka et al., 2011). Hypertension
frequently develops in CKD patients, which not only causes further progressive damage to the
kidneys, but is a major contributing factor to increased risk of cardiovascular events and mortality
(Klag et al., 1996).
There is now compelling evidence that the sympathetic nervous system is over-activated in
CKD. Plasma catecholamine levels have been shown to be increased in hemodialysis patients
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(Henrich et al., 1977). Moreover, patients with end stage renal
disease have elevated muscle sympathetic nerve activity (MSNA)
and that removal of the diseased kidneys, at or following
transplantation of a functional kidney, decreased blood pressure,
peripheral resistance, and the bursting rate in MSNA to normal
values (Converse et al., 1992; Hausberg et al., 2002). Moreover,
it has been reported that ablation of the renal nerves in patients
with CKD, whilst not impacting on renal function itself not
only delayed the deterioration in kidney function but also
resulted in a chronic reduction in blood pressure (Ott et al.,
2015).
It is not clear how the development of CKD may cause
a sympatho-excitation as the disease progresses. Activation of
the renal sympathetic nerves, that is the efferent innervation,
can influence cardiovascular homeostasis by impacting on the
regulation of extracellular fluid volume and hence blood pressure.
This is due to the direct actions of the sympathetic nerves on
renal resistance vessels, to increase vascular resistance and at the
nephrons to stimulate tubular sodium and water reabsorption
(Johns et al., 2011). Increased renal sympathetic nerve activity
(RSNA) will also enhance the release of renin and the generation
of angiotensin II which itself is not only a vasoconstrictor,
but will also act directly on the proximal tubule to stimulate
fluid reabsorption, and indirectly by increasing aldosterone
production which causes sodium reabsorption at the distal
tubule.
The kidney itself contains sensory nerves which have an
important physiological role in the neural control of kidney
function and may contribute to the deranged autonomic control
in CKD (Kopp, 2015). Sensory nerves present in the renal pelvis
appear to be sensitive chemo- and mechano-receptors which
upon activation cause a renal sympatho-inhibition and a renal
nerve dependent natriuresis at the contra-lateral kidney (Dibona
and Rios, 1980). This is termed an inhibitory reno-renal reflex as
it is likely to be involved in ensuring that excretion of a sodium
and water load is distributed equitably between the two kidneys.
There is evidence of an excitatory reno-renal reflex (Ditting
et al., 2012; Johns, 2014) which elicits a sympatho-excitation.
Early evidence by Katholi et al. (1983) using intrarenal adenosine
administration in the dog and Smits and Brody (1984) and more
recently Barry and Johns (2015) using intra-renal bradykinin
infusion in the rat demonstrated acute increases in blood pressure
and RSNA which was blocked in animals subjected to a bilateral
renal denervation.
The recent debate and apparently conflicting findings on the
role of the renal innervation in pathophysiological states in man,
such as resistant hypertension, CKD and diabetes (Bhatt et al.,
2014; Esler, 2014; Krum et al., 2014), has created uncertainty
especially as the underlying physiological mechanisms are
unclear. The hypothesis explored in this investigation was that
injury to the kidney, which may induce inflammatory responses,
would cause an activation of the renal sensory innervation
leading to a renal sympatho-excitation and a dysregulation of
baroreflexes and an inability to excrete a saline volume load
which was mediated by the renal innervation. The model chosen
was the cisplatin induced renal failure ratmodel in which the high
and low pressure baroreflex regulation was tested by increasing
and decreasing blood pressure and administering an acute saline
volume load, respectively.
Methods
Male Wistar rats, weighing 250–300 g were housed under a
12 h light/dark regime at 20 ± 3◦C and 35% humidity. All
procedures were approved by the Animal Experimentation
Ethical Committee at National University Ireland, Cork and
were performed in accordance with the European Community
Directive 86/609/EC. All rats were maintained on a normal diet
and tap water ad libitum.
Cisplatin Induced Renal Failure
Groups of rats were injected with either 5mg/kg cisplatin
(10mg/ml, Hospira, Illinois, USA) in a volume of 6ml/kg to
induce renal injury, or the equivalent volume of saline (0.9%
sodium chloride) intraperitoneally in the control groups of rats
(Khan et al., 2007; Salman et al., 2011). Metabolic studies were
performed over the subsequent 8 day period and acute studies
were undertaken on day 8, post cisplatin administration.
Metabolic Studies
Rats were housed in metabolic cages for 8 days. Urine flow,
sodium excretion, and water intake were measured over 24 h
periods. Day 1 measurements represented basal values and were
obtained prior to administration of either vehicle or cisplatin.
Bilateral renal denervation: Rats were anaesthetized (2–3%
isoflurane in O2). Sequentially, left and right kidneys were
exposed retroperitoneally, each renal artery was identified,
stripped of its adventitia and then coated with a solution of
10% phenol in absolute ethanol for 1min and then rinsed with
saline. In control rats, the renal arteries were only exposed, but
not manipulated further. The muscles and skin were sutured
and an analgesic (carprofen 5mg/kg, Pfizer Inc, USA) given
subcutaneously. The animals were allowed 4 days to recover
before cisplatin administration and entering the metabolic study.
Food was given ad libitum over the 8-day period. Urine
samples and tail vein blood samples (0.4ml) were taken on
Days 1 and 8. The blood samples were centrifuged, the plasma
was removed and frozen at −20◦C. Day 1 and 8 samples
of urine were also frozen at −20◦C. The plasma and urine
sodium concentrations were measured using Flame photometry
(Corning, Halstead, Essex, UK); plasma and urine creatinine
levels were measured (Quanticom Creatinine Assay DICT 500,
Bioassay Systems, Hayward CA, USA) to allow estimation of the
clearance of creatinine. Noradrenaline levels in plasma and urine
were measured using an ELISA (LDN, Nordhorn, Germany).
Noradrenaline excretion rates most likely reflect both filtration
from plasma as well as renal production of the catecholamine and
will be influenced by the ongoing level of glomerular filtration
rate. In order to take account of the low filtration rate in
the RF rats, noradrenaline excretion was calculated per unit
filtrate (creatinine clearance) to attain a more direct measure
of noradrenaline production. On day 8, the animals were killed
with an overdose of anaesthetic (5ml i.p. chloralose-urethane),
the kidneys were excised, decapsulated, the cortices andmedullae
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homogenized, and the supernatent frozen at −80◦C for the later
estimation of TGF-β1 (RnD Systems, Minneapolis, USA).
Acute Studies
General Surgical Preparation: Rats were anaesthetized using 1ml
i.p. of chloralose-urethane (16.5 and 250mg/ml, respectively)
and maintained under anaesthesia with further doses of 0.05ml
every 30min. Rats were prepared for renal nerve recordings
or renal functional measurements from the left kidney as
described previously (Zhang et al., 1997; Huang and Johns, 1998).
Briefly, cannulae were placed in the right femoral artery for
measurement of mean arterial pressure (MAP) and right femoral
vein for administration of sustaining saline and drugs. MAP
and heart rate (Henrich et al.) were recorded using a pressure
transducer (Spectromed, Oxnard, CA, USA) and an amplifier
(Grass Instruments, Quincy, MA, USA). The renal nerves of
the left kidney were dissected free and sealed onto multi-
stranded stainless steel wire recording electrodes (Medwire Mt.
Vernon, NY, USA) using dental glue (Klasse4Dental, Augsburg,
Germany). Following surgical preparation, the rats were allowed
to recover for 2 h before the experimental protocol began.
RSNA is the efferent nerve traffic passing from the spinal
cord to the kidney whereas renal afferent, or sensory, nerve
activity represents that arising within the kidney and passing
to the CNS. In the present study, afferent nerve activity was
not recorded as it was filtered out by the low and high pass
filters in the amplifier. RSNA was verified by audio recognition
and was amplified using an optically isolated amplifier (Grayden
Electronics, Birmingham, UK) having a gain of 100 thousand
with high and low pass filters set at 100 and 1000Hz, respectively.
MAP, HR, and RSNA were recorded using LabVIEW software
(National Instruments, Austin, TX, USA), for oﬄine analysis. At
the end of the experiment the rats were killed with an overdose of
anaesthetic and 20min later, background RSNA was determined
and this value taken from all other RSNA measurements. RSNA
values for all rats were normalized to 100% at baseline levels.
In the acute studies, where left RSNA was recorded, bilateral
renal denervation comprised exposing the right kidney and
denervating it as described above. Thereafter, the nerves of the
left kidney were mechanically occluded between the electrode
and the kidney, just before application of the dental glue, to allow
recording of RSNA only.
Low Pressure Baroreceptor Challenge: This comprised an
acute saline volume expansion where an i.v. infusion of saline
was administered at a rate of 0.25% of body weight per minute for
30min. TheMAP, HR, and RSNA responses to volume expansion
were recorded continuously and averaged over 5min periods for
the duration of the 30min protocol.
High Pressure Baroreceptor Challenge: High pressure
baroreflex regulation of RSNA was evaluated using i.v. doses of
phenylephrine and nitroprusside (10µg in 0.2ml of saline each)
to increase and decrease MAP respectively, by approximately
50–60mmHg. Each drug was infused at a rate of 0.05ml per 10 s
over a 40 s period. The order in which each drug was infused
first was randomized throughout each experiment. A 30min
recovery period was allowed after the infusion of each drug, to
enable RSNA to return to baseline value.
Baroreflex gain curves were generated by plotting the
relationship between RSNA and MAP from oﬄine-stored data.
The voltage level of RSNA recorded in each animal is very much
dependent on technical conditions, anatomical display, ease of
dissecton and fatty tissue surrounding the nerve bundle and
this creates large variability in the signal recorded. In order to
decrease this variability, RSNA was normalized by taking the
basal level recorded immediately prior to the administration of
the vasopressor or vasodepressor agent as 100%. The resultant
sigmoidal relationship was analyzed by means of the following 4
parameter logistic regression equation (Kent et al., 1972), using
the software MATLAB (The Mathworks Inc, Cambridge, UK):
RSNA/HR = A4+ A1
{
1+ exp [A2 ∗ (MAP − A3)]
}
where, A1 is the response range of HR and RSNA, A2 is the
slope of the curve, A3 is the pressure at the midrange of the
curve and A4 is the minimum response of HR and RSNA. A1–A4
values were determined for each rat and a mean value for A1–A4
calculated for each group.
The gain of the baroreflex control of HR and RSNA was
calculated from the first derivative of the logistic equations as
follows:
Gain = −A1.A2.exp (A2 (MAP − A3))/(1
+ exp (A2 (MAP − A3)))2
The maximum slope or gain (Gmax) was calculated at the
midpoint (A3) from the 1st derivative of the logistic function:
Gmax = −A1 ∗A2/4
Renal Functional Protocol: Rats were anaesthetized and prepared
as described above but following exposure of the left kidney, the
ureter was cannulated for urine collection.
Following surgical preparation, the rat was allowed to recover
for 2 h before the experimental protocol began. The protocol
(Figure 1) involved 10 clearance periods (C): two 20min
clearances to determine baseline values, followed by six 5min
collections during the saline volume expansion and then a further
two 20min clearances commencing 30min after the end of the
saline infusion. Plasma samples were collected into heparinized
syringes from the arterial line at the four time points (P1–P4).
The protocol of urine collections and plasma sampling are shown
in Figure 1.
The metabolic study, acute RSNA and renal functional studies
comprised the following groups of animals:
Control rats (n = 12) received a saline i.p. (6ml/kg body
weight)
RF rats (n = 12) were given 5mg/kg of cisplatin i.p.
Bilaterally renally denervated (DNX) rats, control (n = 8)
Bilaterally renally denervated (DNX) RF rats (n = 8).
Statistics
All statistical analyses were performed using Graphpad Prism
Version 6.0c. Results are presented as means ± standard error
of the mean (SEM). For all comparisons, statistical significance
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FIGURE 1 | This illustrates the protocol for urine collections for clearance (C) measurements. C1, C2, C9, and C10 are of 20min duration and C3–C8 are of
5min duration.
was taken at P < 0.05. When multiple groups were compared,
a Two-Way analysis of variance (ANOVA) with Bonferonni’s
corrections for multiple comparisons were used, followed by
Tukey’s post hoc test. Paired and unpaired, two-tailed student’s
t-tests were employed when comparing two groups.
Results
Metabolic Study
Table 1 shows that in the control rats, the fractional excretion
of sodium (FENa), noradrenaline excretion and urine flow rate
did not change from day 1 to 8. By contrast, following cisplatin
administration in the RF rats, FENa and noradrenaline excretion
were some three-fold higher on day 8 (both P < 0.05), although
urine flow rate remained at the same level. Cisplatin given to
the renally denervated rats (RF DNX) had no effect on FENa,
noradrenaline excretion or urine flow rate at day 8 as the values
were not significantly different from those recorded on day 1.
Creatinine clearance (Figure 2) remained at a stable
unchanged value on day 8 in the control rats given vehicle
on day 1. However, in the rats with an intact innervation but
given cisplatin (RF) and those subject to prior renal denervation
(RF DNX), there were significant reductions in creatinine
clearance by day 8 of over 50% (P < 0.001). The day 1 value for
creatinine clearance was significantly (P < 0.001) higher in the
RF DNX compared to the control rats. There were no significant
differences in absolute sodium excretion (UNaV) between any
groups (Table 1 and Figure 2).
TGF-β1
Renal cortical and medullary concentrations of TGF-β1 of
kidneys taken from rats at day 8 were significantly (P < 0.0001)
higher in the cisplatin treated than in control rats (Figure 3).
Noradrenaline
Figure 4 shows that noradrenaline excretion rates did not
change significantly in control rats from day 1 to 8. However,
noradrenaline excretion increased significantly (P < 0.0001)
from baseline levels at day 1 by approximately four fold by
day 8 in the RF group of rats, whereas in the RF DNX group,
noradrenaline excretion at day 8 was not significantly different
from that measured at day 1.
TABLE 1 | Metabolic data in all experimental groups of renal failure (RF),
with (DNX) or without (INN) renal denervation, and control rats.
Group Day 1 Day 8
Body Weight (g) Control INN 272±8 286± 7
RF INN 268±6 248± 12
RF DNX 271±5 281± 7*#
UNaV (µMh−1kg−1) Control INN 157±5 164± 7
RF INN 157±4 154± 6
RF DNX 155±5 159± 5
FENa(%) Control INN 0.9±0.11 0.8± 0.10
RF INN 0.7±0.02# 2.5± 0.36*#
RF DNX 1.12±0.21 4.86± 0.22
NER (ngmL−1h−1) Control INN 0.037±0.006 0.024± 0.005
RF INN 0.053±0.005 0.189± 0.024*#
RF DNX 0.045±0.010 0.063± 0.013
GFR (mLmin−1kg−1) Control INN 2.3±0.2 2.0± 0.1
RF INN 2.7±0.3# 1.1± 0.2*#
RF DNX 4.0±0.2* 1.4± 0.5
UV (mLh−1kg−1) Control INN 1.0±0.1 0.5± 0.1
RF INN 1.6±0.3 1.8± 0.5*
RF DNX 0.5±0.1 0.6± 0.2
Statistical analysis was performed using Two-Way ANOVA followed by Tukey’s post hoc
test. Data presented as mean SEM. (Control INN n = 12, RF and RF DNX, n = 8 per
group). UNaV, absolute sodium excretion; FENa, fractional excretion of sodium; NER,
noradrenaline excretion rate; GFR, glomerular filtration rate (creatinine clearance); UV,
urine flow rate. *P < 0.05 vs. control INN, #P < 0.05 vs. RF DNX.
Acute Studies
High Pressure Baroreflex challenge: It can be seen from Table 2
that baseline values of HR and MAP were not different in all
groups of rats. Basal integrated RSNA was significantly (P <
0.005) higher in the RF group when compared with all other
groups. In the RF animals, both the range (A1) and the slope (A2)
of the gain curve were significantly lower and mid-point blood
pressure (A3) higher (P < 0.05, <0.01, and <0.05, respectively)
compared to those of the control rats although and the minimum
point to which RSNA could be driven (A4) were no different.
Renal denervation of the control rats had little effect on the
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FIGURE 2 | Creatinine clearance (glomerular filtration rate, GFR), upper
graph (A) and sodium excretion (Lower graph, B) for innervated (INN)
control, renal failure (RF INN) and renally denervated RF (RF DNX) rats
on day 1 and 8 of the metabolic study. Statistical analysis was performed
using Two-Way ANOVA followed by Tukey’s post-hoc test. Data presented as
mean SEM. (n = 12 for all groups). *P < 0.05 vs. Control INN; #P < 0.05 vs.
RF DNX. P-value for interaction <0.005.
values of A1, A2, or A3, although A4 was reduced. However,
following renal denervation in the RF rats the values of A1,
A2, A3, and A4 could not be distinguished statistically from
those of the control DNX rats. These findings are illustrated
as full baroreceptor gain curves in Figure 5. Figure 6 presents
the maximal gain of the RSNA baroreflex curve for all groups
and it was significantly (P < 0.05) lower in the RF compared
to the control rats. Furthermore, renal denervation of the RF
rats (RF DNX) resulted in maximal gain values for RSNA which
were no different from either the control or control DNX groups
of rats.
Low pressure baroreflex challenge: The infusion of the
acute saline load (Figure 7) significantly decreased RSNA by
approximately 50% after 30min in both the intact control rats
and those subjected to renal denervation (both P < 0.05). By
contrast, in the RF rats, the acute saline load did not change
RSNA, which was a response significantly (P < 0.002) different
from that obtained in the control rats. However, after prior
renal denervation of the RF rats, the 30min of saline infusion
decreased RSNA to the same degree as that obtained in the
control and control DNX groups of rats, and to a significantly
(P < 0.001) greater degree than that obtained in the intact RF
group (Figure 7).
The excretory responses of all groups of rats control and renal
failure rats over the course of the volume expansion are presented
FIGURE 3 | This presents the renal cortical and medullary
concentrations of TGF-β1 in control and RF groups of rats. *P < 0.001
vs. Control INN.
FIGURE 4 | This provides the fractional noradrenaline excretion rates
(ng/mlGFR/h) for innervated control, innervated cisplatin treated (RF
INN) and renally denervated renal failure (RF DNX) rats. Statistical
analysis was performed using Two-Way ANOVA followed by Tukey’s post hoc
test. Data presented as mean SEM. (n = 12 for all groups). *P < 0.05 vs.
Control INN #P < 0.05 vs. RF DNX. P-value for interaction <0.0001.
TABLE 2 | Baseline mean arterial pressure (MAP), heart rate (HR) and renal
sympathetic nerve activity (RSNA) and baroreflex gain curve parameters.
Control INN RF INN Control DNX RF DNX
Baseline HR (beats min−1 ) 346± 27 347± 13 358± 18 361± 20
Baseline MAP (mmHg) 94± 7 83± 4 72± 5 78± 3
Baseline RSNA (mVs−1 ) 7± 3 29± 6*# 4± 1 2± 0.3
A1 (% RSNA) 98± 19 43± 15* 103± 8 98± 15
A2 (% RSNA mmHg−1) 0.14± 0.01 0.07± 0.02*# 0.11± 0.03 0.14± 0.02
A3 (mmHg) 94± 17 138± 17*# 88± 8 104± 6
A4 (% RSNA) 68± 23 68± 9# 31± 2 37± 7
A1, the range of the curve; A2, the slope or sensitivity of the curve; A3, the mid-point blood
pressure; and A4, theminimumpoint to which the RSNA could be driven in all experimental
groups. Renal failure (RF) and control rats, with (DNX) or without (INN) renal denervation.
Statistical analysis was performed using Two-Way ANOVA followed by Tukey’s post hoc
test. Data presented as mean SEM. (n = 12 for control and n = 8 for RF groups). *P <
0.05 vs. control INN; *P < 0.005 vs. control #P < 0.05 vs. RF DNX.
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FIGURE 5 | Baroreflex curves for RSNA (%), generated from mean A1–A4 values for control innervated (control INN) and denervated (control DNX) and
renal failure (RF) innervated (RF INN) and denervated (RF DNX) groups.
in Figure 8. The acute volume load significantly increased UV
and UNaV from 81.1 ± 2.0 to 1941.3 ± 67.5µl/min/kg and
0.22 ± 0.01 to 25.24 ± 6.66µmol/ml/kg, respectively in the
control group and to a significantly greater extent in the control
rats subjected to renal denervation, from 78.3± 19.1 to 2665.5±
598.5µl/min/kg and 0.23 ± 0.01 to 34.65 ± 5.97µmol/ml/kg,
respectively (P < 0.01). The magnitude of increase in UV was
significantly (P < 0.001) larger in the control compared to the RF
group. The magnitudes of increase in UV and UNaV in response
to the saline volume expansion were significantly blunted in the
RF rats (both P < 0.001) but not in the RF DNX rats in which the
increases in UV and UNaV were similar to those of the control
rats.
Discussion
The role of the renal sensory innervation in the regulation
of autonomic and renal function remains enigmatic. There
has recently been renewed interest in the contribution of the
renal innervation in specific patient groups; those with resistant
hypertension (Krum et al., 2014), chronic renal disease (Ott et al.,
2015) and diabetes and obesity (Mahfoud et al., 2011). However,
the apparent failure of the Symplicity HTN3 trial (Bhatt et al.,
2014) has called into question the contribution of the renal nerves
in these patho-physiological states and indicates that further
study is necessary.
The present investigation set out to explore how renal failure
following injury to the kidney with cisplatin impacted on the
neural regulation of kidney function. There were two novel
findings. Firstly, that the cisplatin induced renal injury was
associated with a sympatho-excitation, as shown by the increase
in fractional noradrenaline excretion, and that it was an effect
dependent on an intact renal innervation. Secondly, that the
deranged high and low pressure baroreflex regulation of RSNA
following the renal injury with cisplatin resulted in a blunted
ability to excrete a sodium load and, moreover, was dependent
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FIGURE 6 | This illustrates the maximal gain of the RSNA baroreflex
curve for intact control (Control INN), control renally denervated rats
(control DNX), cisplatin treated renal failure (RF) and renally
denervated renal failure (RF DNX) groups of rats. Statistical analysis was
performed using Two-Way ANOVA followed by Tukey’s post hoc test. Data
presented as mean SEM. (n = 12 for all groups). *P < 0.05 vs. Control INN;
#P < 0.05 vs. RF DNX.
FIGURE 7 | This compares the changes in renal sympathetic nerve
activity (RSNA) in response to the saline volume expansion at baseline
(over the 5min prior to the start of infusion) and over the last 5min of
the infusion (30min) in intact control (Control INN), control renally
denervated rats (control DNX), intact cisplatin treated renal failure (RF)
and renally denervated renal failure (RF DNX) groups of rats. Statistical
analysis was performed using Two-Way ANOVA followed by Tukey’s post hoc
test. Data presented as mean SEM. (n = 12 for all groups). *P < 0.001 against
baseline. P-value for interaction <0.005.
on the renal innervation as the natriuretic and diuretic responses
were normalized following removal of the renal innervation.
These findings reveal that the injured and failing kidney seems to
elicit an activation of the renal sensory innervation which blunts
sympathetic control preventing the dynamic regulation of renal
excretory function necessary for the regulation of extracellular
fluid volume and hence the chronic level at which blood pressure
is set.
The administration of a single dose of cisplain caused a
marked reduction in creatinine clearance indicative of decreased
glomerular filtration comparable to that reported earlier using
this model (Khan et al., 2007). This likely reflects damage
caused by cisplatin to the proximal epithelial cells, which slough
off and generate hyaline casts that in turn block the tubules
decreasing filtration. Indeed, injury to the kidney is supported
by the observation that concentrations of TGF-β1, a biomarker
of renal damage and fibrosis (Bottinger, 2007), was increased
to high levels in both the renal cortex and medulla by day 8.
One of the consequences of cisplatin induced renal injury will
be an activation of the renin-angiotensin-aldosterone system.
Any increase in angiotensin II production will contribute to the
deterioration in renal function in two ways, directly by causing
constriction of the renal resistance vessels, and indirectly via a
facilitation of noradrenaline release from the varicosities of the
postganglionic sympathetic fibers at the neuroeffector junctions.
Although the cisplatin injury decreased creatinine clearance,
absolute sodium excretion was maintained at levels comparable
to those of the control rats, but this most likely reflects an
adjustment of fluid handling along the later portions of the
nephrons. The end result was that by day 8, fractional sodium
excretion, was markedly elevated in the cisplatin treated rats,
which indicated that there was decreased reabsorption of fluid
along the nephron as a greater proportion of the filtered load was
excreted. It was clear that in the renal failure group subjected
to the renal denervation, following the cisplatin challenge there
was a similarly elevated fractional sodium excretion by day 8
suggesting that the renal sympathetic innervation was playing a
minor role in the regulation of basal fluid excretion under these
conditions.
A primary aim of the investigation was to determine
whether in the cisplatin model of renal injury there was an
excitation of the sympathetic nervous system. To this end, the
urinary excretion of noradrenaline was evaluated. Fractional
noradrenaline excretion was evaluated even though this was
a less reliable indicator of sympathetic nerve activity in the
kidney than measurement of noradrenaline content, but it did
have the advantage of allowing repeated measures in the same
animals. The first novel finding was that fractional noradrenaline
excretion was markedly elevated by day 8, indicative of an
increase in sympathetic activity. It is likely that there are two
sources of noradrenaline in the kidney, that filtered from the
plasma, and that released at the neuroeffector junctions of the
renal sympathetic innervation. Clearly, there is a reduced filtered
load of both fluid and noradrenaline in the injured kidney
but if this was taken into account, by calculating fractional
noradrenaline excretion, then it became evident that that there
was a large increase in noradrenaline excreted by the kidney.
This conclusion was supported by the observation that in the
animals subjected to the bilateral renal denervation, there was no
change in fractional noradrenaline excretion on day 8, compared
with baseline, following the cisplatin injection even though there
was a comparable reduction in glomerular filtration rate. A
limitation of the present study was that a group of control rats
subjected to renal denervation were not studied but there was a
low probability that any major responses in renal function would
have occurred over the 8 day period of study. Interestingly, the
level of RSNA recorded from the multifiber nerve recordings in
the acute studies was higher in the renal failure model compared
with the control rats. However, such a direct comparison of this
nature is not valid because there are technical challenges which
impact on the ability to get consistent nerve recordings between
animals because of differing anatomical displays, the ability to
clear fatty tissue from the nerve bundle and the number of nerve
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FIGURE 8 | This presents the values of urine flow (UV) and sodium
excretion (UNaV) for each of the 5min periods during the 30min of
saline volume expansion in control, control renally denervated rats
(control DNX), cisplatin treated renal failure (RF) and renally
denervated renal failure (RF DNX) groups of rats. Statistical analysis
was performed using Two-Way ANOVA followed by Tukey’s post hoc test.
Data presented as mean SEM. (n = 12 for all groups). *P < 0.01 vs. control
#P < 0.05 vs. RF DNX. P-value for interaction is <0.001.
bundles that can be placed on the electrodes. Together, these
findings imply that there is a sympatho-excitation following the
cisplatin induced renal failure but perhaps more importantly,
they suggest that it is the kidney which is the source of the sensory
information passing into the central nervous system. Moreover,
these observations closely reflect the reports in chronic renal
disease in man where an elevated level of sympathetic activity has
been reported (Converse et al., 1992; Hausberg et al., 2002).
The second major objective of the investigation was to
determine how the cisplatin induced renal injury disrupted
the baroreflex regulation of RSNA and renal nerve dependent
excretory function. It was evident that there were marked
alterations in the baroreflex gain curves in the renal failure
rats. Perhaps surprising was the elevation in mid-point blood
pressure (A3) in renal failure at a time when basal blood pressure
was similar to that of the control rats. The reasons are unclear
but one possibility is that basal blood pressure is influenced by
the level of anaesthesia whereas the baroreflex gives a better
reflection of the overall regulatory mechanisms that determine
the level at which blood pressure is set. The maximal gain of
the high pressure baroreflex was very much depressed in the
renal failure rats demonstrating that autonomic control was
blunted. Importantly, bilateral renal denervation restored the
maximal gain of the baroreflex to normal values indicating that
a neural signal was originating from the kidneys under these
circumstances. These findings support an earlier report in renal
failure in rats (Khan et al., 2014) evaluating slightly different
characteristics of the baroreflex curves but nevertheless also
demonstrate major dysfunction in baroreflex regulation in renal
failure. Nonetheless, injury to the kidney elicits an inappropriate
neural signal which, within the CNS, blunts normal high pressure
baroreflex regulation of at least one major organ, the kidney, and
could seriously impair cardiovascular homeostasis.
Challenging the cardiopulmonary reflex using an acute saline
volume expansion caused a prompt renal sympatho-inhibition,
which was a response absent in the renal failure animals but that
could be restored by prior renal denervation. These observations
support those of Khan et al. (2014) and reinforce the concept
that inappropriate sensory information arising from the injured
kidneys impairs the normal operation of the cardiopulmonary
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reflex. The second important novel observation was that the
ability to increase sodium and water excretion in response to
the volume expansion was very much attenuated but could be
restored if the influence of the renal nerves was removed. Two
interesting points arise from this observation. Firstly, that part
of the inability to excrete the saline load in the renal failure rats
could be due to the increased RSNAwhich, via the direct action of
the nerves on proximal tubular fluid reabsorption, would cause a
relative fluid retention. Secondly, the restoration of the excretory
responses in the renal failure rats following renal denervation was
compatible with an inappropriate sensory signal arising from the
injured kidneys which was both causing an elevated RSNA as well
as blunting the normal renal sympatho-inhibitory response to a
volume expansion.
This investigation set out to examine how injury to the
kidney, induced by cisplatin, caused a derangement of the
reflex regulation of RSNA and the neural regulation of kidney
excretory function. There is good evidence that in experimental
models and man CKD is associated with a sympatho-excitation
that may be due to the intra-renal generation of inflammatory
mediators (Campese and Kogosov, 1995; Campese et al., 2011;
Koeners et al., 2014). It was apparent in the present study that
cisplatin induced renal failure was associated with an increased
noradrenaline excretion consistent with a sympatho-excitation.
There was also a marked attenuation of both the high and
low pressure baroreflex regulation of RSNA and in terms of
function, prevented the volume expansion mediated natriuresis
and diuresis. Derangement of these reflexes means that the
dynamic handling of sodium and water during normal everyday
activity is lost which will seriously impact on cardiovascular
homeostasis. Importantly, these dysfunctions appear dependent
on the renal innervation as they are normalized when the kidneys
are denervated. The question arises as to how an inappropriate
sensory signal is generated within the kidneys under these
conditions. In this renal failure model, an inflammatory
response takes place as expressed by the increase in TGF-
β1 concentrations within the kidney. One significant pro-
inflammatory mediator within the kidney is bradykinin which is
a key mediator of increased sensory nerve activity (Kopp, 2015)
and recently it has been reported that intra-renal bradykinin
infusion can increase RSNA, but not if the infused kidney is
denervated (Barry and Johns, 2015). It may well be that an
inflammatory response induced by renal injury is responsible
for the deranged neural control of the kidney as renal disease
develops.
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